,i #aai? ,,congress #a/ ,session ,h4 ,r4 #ejcb ,,9 ,,! ,,h\se ,,( ,,repres5tatives ,augu/ #bb1 #bjbe,mr4 ,v9dman 7= himself & ,mr4 ,baumg>tn]7 introduc$ ! foll[+ bill2 :i* 0 ref]r$ to ! ,committee on ,en]gy & ,comm]ce1 & 9 addition to ! ,committee on ! ,judici>y1 = a p]iod to be subsequ5tly det]m9$ by ! ,speak]1 9 ea* case = consid]ation ( su* provisions z fall )9 ! jurisdiction ( ! committee conc]n$ ,a ,,bill ,to am5d ! ,controll$ ,sub/ances ,act to p]man5tly s*$ule ! class ( b5zimidazole-opioids kn[n z nitaz5es1 & = o!r purposes4 #a4 ,%ort title ,?is ,act may be cit$ z ! ,nitaz5e ,control ,act4 #b4 ,f9d+s ,congress f9ds ! foll[+3 7#a7 ,nitaz5es are a class ( syn!tic opioids fir/ syn!siz$ 9 ! #aiejs t exhibit extreme pot5cy at ! mu-opioid receptor1 ) "s analogs exce$+ ! pot5cy ( f5tanyl4 7#b7 ,! ,drug ,en=cem5t ,adm9i/ration 7,,dea7 has tempor>ily or p]man5tly s*$ul$ multiple nitaz5e comp\nds "u ,s*$ule ,i ( ! ,controll$ ,sub/ances ,act due to _! high abuse pot5tial & lack ( accept$ m$ical use4 7#c7 ,nitaz5es & nitaz5e analogues h em]g$ 9 ! illicit drug supply z design] drugs & contribute to ov]dose & fatal poison+s 9 ! ,unit$ ,/ates4 7#d7 ,a class-wide p]man5t s*$ul+ ( nitaz5es is necess>y to preemptively address ! prolif]ation ( new analogs1 /reaml9e en=cem5t1 & protect public heal?4 #c4 ,s*$ule ,i classification ( nitaz5es 7a7 ,am5dm5t ,section #bjb7;c7 ( ! ,controll$ ,sub/ances ,act 7#ba ,u4,s4,c4 #hab7;c77 is am5d$ by add+ at ! end ( ,s*$ule ,i ! foll[+3 7f7 ,b5zimidazole-opioids1 commonly ref]r$ to z nitaz5es1 includ+ any sub/ance 7includ+ its salts1 isom]s1 & salts ( isom]s7 t has a *emical /ructure t is sub/antially simil> to t ( etonitaz5e or isotonitaz5e1 includ+3 7#a7 ,a b5zimidazole core sub/itut$ at ! #b-position ) a b5zyl or sub/itut$ b5zyl gr\p2 & 7#b7 ,a basic nitrog5-conta9+ side *a9 at ! #a-position2 & 7#c7 ,exhibits agoni/ activity at ! mu-opioid receptor4 ,su* sub/ances include1 b are n limit$ to3 etonitaz5e1 clonitaz5e1 metonitaz5e1 isotonitaz5e1 protonitaz5e1 butonitaz5e1 etodesnitaz5e1 flunitaz5e1 ,n-pyrrolid9o etonitaz5e1 ,n-dese?yl isotonitaz5e1 & ,n-pip]id9yl etonitaz5e4 4 7b7 ,removal ( tempor>y /atus ,any sub/ance includ$ 9 ! am5dm5t to section #bjb7;c7 ( ! ,controll$ ,sub/ances ,act made by ?is section t 0 tempor>ily s*$ul$ "u section #bja7;h7 ( ! ,controll$ ,sub/ances ,act %all be deem$ p]man5tly s*$ul$ & subject to ! requirem5ts ( ,s*$ule ,i z ( ! date ( enactm5t ( ?is ,act4 7c7 ,rulemak+ au?ority ,! ,attorney ,g5]al1 9 consultation ) ! ,secret>y ( ,heal? & ,human ,s]vices1 may issue rules to cl>ify ! scope ( ! nitaz5e class z necess>y to en=ce ?is section1 provid$ su* rules are consi/5t ) ! *emical def9ition 9 subsection 7a77#a74 7d7 ,rese>* exemption 7#a7 ,not)/&+ ! am5dm5ts made by subsection 7a71 a rese>*] :o1 z ( ! date ( enactm5t ( ?is ,act1 is conduct+ rese>* involv+ a sub/ance describ$ 9 subsection 7a7 t 0 n previ\sly li/$ 9 ,s*$ule ,i ( section #bjb7;c7 ( ! ,controll$ ,sub/ances ,act 7#ba ,u4,s4,c4 #hab7;c771 %all n be requir$ to obta9 a regi/ration "u section #cjc7;f7 ( su* ,act 7#ba ,u4,s4,c4 #hbc7;f77 solely due to ! inclusion ( t sub/ance 9 ,s*$ule ,i1 provid$ t3 7,a7 ! rese>* is be+ conduct$ pursuant to an active inve/igational new drug 7,,ind7 application or o!r applicable regulatory exemption recogniz$ by ! ,food & ,drug ,adm9i/ration or ,drug ,en=cem5t ,adm9i/ration2 7,b7 ! rese>* 0 approv$ by an in/itutional review bo>d 7,,irb7 prior to ! enactm5t ( ?is ,act2 & 7,c7 ! rese>*] notifies ! ,attorney ,g5]al1 9 a mann] det]m9$ by ! ,attorney ,g5]al1 )9 #ij days ( enactm5t ( ?is ,act4 7#b7 ,! exemption "u p>agraph 7#a7 %all rema9 9 effect = a p]iod n to exce$ #ah mon?s f ! date ( enactm5t1 dur+ :i* "t ! rese>*] may apply = a regi/ration "u section #cjc7;f71 & ! ,attorney ,g5]al %all exp$ite su* applications to ensure cont9uity ( rese>*4 7#c7 ,no?+ 9 ?is subsection %all be con/ru$ to au?orize ! initiation ( new rese>* us+ sub/ances describ$ 9 subsection 7a7 )\t prop] regi/ration & s*$ul+ compliance4